Sign In
Buy PLRX
$1.18
+0.0200 (+1.72%)
At Close: Jun 03, 2026
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
04:23am, Thursday, 26'th Jan 2023
Patients with this condition have difficulty breathing due to a buildup of lung scar tissue. They have difficulty breathing due to built-up scar tissue in their lungs.
Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why
12:02pm, Wednesday, 25'th Jan 2023
Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.
An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50%
10:12am, Monday, 23'rd Jan 2023
Pliant Therapeutics unveiled promising results for a lung disease treatment on Monday, and PLRX stock rocketed into the stratosphere. The post An Unexpected Feat Just Sent Pliant Therapeutics Soaring
Pliant Therapeutics shares rally 75%
07:49am, Monday, 23'rd Jan 2023
Shares of Pliant Therapeutics Inc. PLRX, +2.62% soared about 75% in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibro
Strength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength?
06:02am, Thursday, 12'th Jan 2023
Pliant Therapeutics, Inc. (PLRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in
Pliant Therapeutics: Wait For More Data Clarity On Dose-Dependent Response In FVC
03:48am, Friday, 16'th Dec 2022
Pliant Therapeutics' phase 2a data does not show a dose-dependent response in FVC. I discussed some of the other confusing issues here.
Pliant Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 15'th Nov 2022
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics
Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates
06:48pm, Tuesday, 08'th Nov 2022
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 12.16% and 34.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
01:40pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Here is how Assertio (ASRT) and Pliant Therapeutics, Inc. (PLRX) have performed compared to their sector so far this year.
3 Soaring Biotech Stocks That Could Climb Much Higher
09:33am, Thursday, 20'th Oct 2022 The Motley Fool
These drugmakers have bucked the overall market's downward trend this year and expectations are still high.
AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem
04:02pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023. Stock up.
Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors
10:30pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to imp
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
08:04am, Thursday, 22'nd Sep 2022 Benzinga
Gainers
Stabilis Solutions, Inc. (NASDAQ: SLNG) shares climbed 71.3% to close at $8.84 after the company announced it has received authorization from the U.S. Department of Energy to export domestic
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
04:40pm, Wednesday, 21'st Sep 2022 Benzinga
Gainers
Stabilis Solutions, Inc. (NASDAQ: SLNG) shares jumped 108% to $10.73 after the company announced it has received authorization from the U.S. Department of Energy to export domestically produ
Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate
02:12pm, Wednesday, 07'th Sep 2022 Zacks Investment Research
Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.
